Antibodies for the Delivery of Radionuclides

Drug Delivery in Oncology: From Basic Research to Cancer Therapy

Volumn 2, Issue , 2011, Pages 411-439

  Wu, Anna M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ImmunoPET; Pretargeting; Radioimmunoimaging; Radioimmunotherapy; SPECT

Indexed keywords

EID: 84887141952     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527634057.ch15     Document Type: Chapter

References (71)

1. Nwe, K. and Brechbiel, M.W. (2009) Growing applications of ''click chemistry'' for bioconjugation in contemporary biomedical research. Cancer Biother. Radiopharm., 24, 289-302.
2. Kwakkenbos, M.J., Diehl, S.A. et al. (2009) Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat. Med. 16, 123-128.
3. Boswell, C.A., and Brechbiel, M.W. (2007) Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl. Med. Biol., 34, 757-778.
4. Mohmood, U., (2009) MICoE Task Force looks to the future. J. Nucl. Med., 50, 15N.
5. Pagani, M., Stone-Elander, S. et al. (1997) Alternative positron emission tomography with non-conventional positron emitters: effects of their physical properties on image quality and potential clinical applications. Eur. J. Nucl. Med., 24, 1301-1327.
6. Nayak, T.K., and Brechbiel, M.W. (2009) Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges. Bioconjug. Chem., 20, 825-841.
7. Schubiger, P.A., Alberto, R. et al. (1996) Vehicles, chelators, and radionuclides: choosing the ''building blocks'' of an effective therapeutic radioimmunoconjugate. Bioconjug. Chem., 7, 165-179.
8. Brechbeil, M.W. (2007) Targeted alpha-therapy: past, present, future?. Dalton Trans., 4918-4928.
9. Wilbur, D.S. (1992) Radiohalogenation of proteins: an overview of radionuclides, labeling methods, and reagents for conjugate labeling. Bioconjug. Chem., 3, 433-470.
10. Volkert, W.A., Goeckeler, W.F. et al. (1991) Therapeutic radionuclides: production and decay property considerations. J. Nucl. Med., 32, 174-185.
11. Waibel, R., Alberto, R. et al. (1999) Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat. Biotechnol., 17, 897-901.
12. Vaidyanathan, G., and Zalutsky, M.R. (2008) Astatine radiopharmaceuticals: prospects and problems. Curr. Radiopharm., 1, 177.
13. Zalutsky, M.R., Reardon, D.A. et al. (2008) Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J. Nucl. Med., 49, 30-38.
14. Costantini, D.L., Bateman, K. et al. (2008) Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate. J. Nucl. Med., 49, 1498-1505.
15. Costantini, D.L., Hu, M. et al. (2008) Peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications. Cancer Biother. Radiopharm., 23, 3-24.
16. McCabe, K.E., Wu, A.M. (2010) Positive progress in ImmunoPET - not just a coincidence. Cancer Biother. Radiopharm., 25, 253-261.
17. Borsi, L., Balza, E. et al. (2002) Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int. J. Cancer, 102, 75-85.
18. Kenanova, V., Olafsen, T. et al. (2005) Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res., 65, 622-631.
19. Kenanova, V., Olafsen, T. et al. (2007) Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy. Cancer Res., 67, 718-726.
20. Westera, G., Reist, H.W. et al. (1991) Radioimmuno positron emission tomography with monoclonal antibodies: a new approach to quantifying in vivo tumour concentration and biodistribution for radioimmunotherapy. Nucl. Med. Commun., 12, 429-437.
21. Garg, P.K., Garg, S. et al. (1991) Fluorine-18 labeling of monoclonal antibodies and fragments with preservation of immunoreactivity. Bioconjug. Chem., 2, 44-49.
22. Anderson, C.J., Connett, J.M. et al. (1992) Copper-64-labeled antibodies for PET imaging. J. Nucl. Med., 33, 1685-1691.
23. Page, R.L., Garg, P.K. et al. (1994) PET imaging of osteosarcoma in dogs using a fluorine-18-labeled monoclonal antibody Fab fragment. J. Nucl. Med., 35, 1506-1513.
24. Wu, A.M., and Senter, P.D. (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol., 23, 1137-1146.
25. Olafsen, T., and Wu, A.M. (2010) Antibody vectors for imaging. Semin. Nucl. Med., 40, 167-181.
26. Olafsen, T., Gu, Z. et al. (2007) Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J. Immunother., 30, 396-405.
27. Leyton, J.V., Olafsen, T. et al. (2008) Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors. Clin. Cancer Res., 14, 7488-7496.
28. Hu, S., Shively, L. et al. (1996) Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res., 56, 3055-3061.
29. Wu, A.M., Williams, L.E. et al. (1999) Anti-carcinoembryonic antigen (CEA) diabody for rapid tumor targeting and imaging. Tumor Target., 4, 47-58.
30. Wu, A.M., Yazaki, P.J. et al. (2000) High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc. Natl. Acad. Sci. USA, 97, 8495-8500.
31. Sundaresan, G., Yazaki, P.J. et al. (2003) 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J. Nucl. Med., 44, 1962-1969.
32. Adams, G.P., Schier, R. et al. (1998) Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br. J. Cancer, 77, 1405-1412.
33. Gonzalez Trotter, D.E., Manjeshwar, R.M. et al. (2004) Quantitation of small-animal 124I activity distributions using a clinical PET/CT scanner. J. Nucl. Med., 45, 1237-1244.
34. Olafsen, T., Betting, D. et al. (2006) MicroPET imaging of CD20 lymphoma xenografts using engineered antibody fragments. J. Nucl. Med., 47, 33P.
35. Lepin, E.J., Leyton, J.V. et al. (2010) An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur. J. Nucl. Med. Mol. Imaging, 37, 1529-1538.
36. Rossin, R., Berndorff, D. et al. (2007) Small-animal PET of tumor angiogenesis using a 76Br-labeled human recombinant antibody fragment to the ED-B domain of fibronectin. J. Nucl. Med., 48, 1172-1179.
37. Smith-Jones, P.M., Solit, D. et al. (2006) Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J. Nucl. Med., 47, 793-796.
38. Cai, W., Olafsen, T. et al. (2007) PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J. Nucl. Med., 48, 304-310.
39. Liu, K., Lepin, E.J. et al. (2011) Microfluidic-based biomolecule radiolabeling for immunoPET. Mol. Imaging, 10, 168-176.
40. Lewis, M.R., Wang, M. et al. (2003) In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy. J. Nucl. Med., 44, 1284-1292.
41. Schuhmacher, J., Klivenyi, G. et al. (1995) Multistep tumor targeting in nude mice using bispecific antibodies and a gallium chelate suitable for immunoscintigraphy with positron emission tomography. Cancer Res., 55, 115-123.
42. Klivenyi, G., Schuhmacher, J. et al. (1998) Gallium-68 chelate imaging of human colon carcinoma xenografts pretargeted with bispecific anti-CD44V6/anti-gallium chelate antibodies. J. Nucl. Med., 39, 1769-1776.
43. Schuhmacher, J., Kaul, S. et al. (2001) Immunoscintigraphy with positron emission tomography: gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies. Cancer Res., 61, 3712-3717.
44. Aarts, F., Boerman, O.C. et al. (2010) Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti-di-diethylenetriaminepentaacetic acid F(ab́)2 antibody. Cancer, 116 (Suppl. 4), 1111-1117.
45. Kraeber-Bodere, F., Salaun, P.Y. et al. (2010) Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer. Cancer, 116 (Suppl. 4), 1118-1125.
46. Rossi, E.A., Sharkey, R.M. et al. (2003) Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. Clin. Cancer Res., 9, 3886S-3896S.
47. McBride, W.J., Zanzonico, P. et al. (2006) Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide. J. Nucl. Med., 47, 1678-1688.
48. Goldenberg, D.M., Rossi, E.A. et al. (2008) Multifunctional antibodies by the dock-and-lock method for improved cancer imaging and therapy by pretargeting. J. Nucl. Med., 49, 158-163.
49. Sharkey, R.M., Karacay, H. et al. (2007) Bispecific antibody pretargeting of radionuclides for immuno single-photon emission computed tomography and immuno positron emission tomography molecular imaging: an update. Clin. Cancer Res., 13, 5577s-5585s.
50. Sharkey, R.M., Karacay, H. et al. (2008) Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model. Radiology, 246, 497-507.
51. Wilson, C.B., Snook, D.E. et al. (1991) Quantitative measurement of monoclonal antibody distribution and blood flow using positron emission tomography and 124iodine in patients with breast cancer. Int. J. Cancer, 47, 344-347.
52. Larson, S.M., Pentlow, K.S. et al. (1992) PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J. Nucl. Med., 33, 2020-2023.
53. Jayson, G.C., Zweit, J. et al. (2002) Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J. Natl. Cancer Inst., 94, 1484-1493.
54. Aide, N., Cappele, O. et al. (2003) Efficiency of [18F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur. J. Nucl. Med. Mol. Imaging, 30, 1236-1245.
55. Kang, D.E., White, R.L. Jr. et al. (2004) Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J. Urol., 171, 1806-1809.
56. Divgi, C.R., Pandit-Taskar, N. et al. (2007) Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol., 8, 304-310.
57. Borjesson, P.K., Jauw, Y.W. et al. (2006) Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin. Cancer Res., 12, 2133-2140.
58. Zalutsky, M.R. (2006) Potential of immuno-positron emission tomography for tumor imaging and immunotherapy planning. Clin. Cancer. Res., 12, 1958-1960.
59. Dijkers, E.C., Oude Munnink, T.H. et al. (2010) Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin. Pharmacol. Ther., 87, 586-592.
60. Larson, S.M., El-Shirbiny, A.M. et al. (1997) Single chain antigen binding protein (sFv CC49). First human studies in colorectal carcinoma metastatic to liver. Cancer, 80, 2458-2468.
61. Begent, R.H., Verhaar, M.J. et al. (1996) Clinical evidence of efficient tumortargeting based on single-chain Fv antibody selected from a combinatorial library. Nat. Med., 2, 979-984.
62. Mayer, A., Tsiompanou, E. et al. (2000) Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. Clin. Cancer Res., 6, 1711-1719.
63. Wong, J.Y., Chu, D.Z. et al. (2004) Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clin. Cancer Res., 10, 5014-5021.
64. Santimaria, M., Moscatelli, G. et al. (2003) Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin. Cancer Res., 9, 571-579.
65. Sauer, S., Erba, P.A. et al. (2009) Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood, 113, 2265-2274.
66. DeNardo, S.J., DeNardo, G.L. et al. (1988) Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies. Int. J. Cancer Suppl., 3, 96-101.
67. Deshpande, S.F., DeNardo, S.J. et al. (1988) Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice. J. Nucl. Med., 29, 217-225.
68. Palanca-Wessels, M.C., and Press, O.W. (2010) Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas. Cancer 116 (Suppl. 4), 1126-1133.
69. Macklis, R.M. (2007) Radioimmunotherapy as a therapeutic option for non-Hodgkin's lymphoma. Semin. Radiat. Oncol., 17, 176-183.
70. Tagawa, S.T., Beltran, H. et al. (2010) Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer, 116 (Suppl. 4), 1075-1083.
71. Wong, J.Y., Raubitschek, A. et al. (2010) A pretherapy biodistribution and dosimetry study of indium-111-radiolabeled trastuzumab in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. Cancer Biother. Radiopharm., 25, 387-394.